Journal of Experimental and Clinical Cancer Research Submission Guide: What to Prepare Before You Submit

JECCR is broad across oncology topics, but it is selective about the kind of cancer story it wants.

Editors are usually asking:

• does this manuscript contain a significant cancer-research advance
• is there a real translational bridge rather than a generic clinical relevance claim
• do the biomarkers, targets, or mechanisms connect credibly to diagnosis, treatment, or resistance
• is the paper strong enough for a broad oncology readership rather than a narrower specialty lane

That is why purely descriptive tumor biology and thinly translational biomarker papers often struggle here.

The journal is broad enough to cover many oncology formats, but the common requirement is that the bridge to diagnosis, treatment, resistance, or patient selection feels structurally tied to the evidence rather than added as hopeful framing.

The live journal guidance is unusually clear about what kind of oncology paper belongs here.

The practical implication is that JECCR wants more than "interesting cancer biology." It wants a paper that already behaves like translational oncology.

It also wants operational readiness. At journals with this kind of translational positioning, weak declarations, incomplete ethics language, or late disclosure cleanup can make a manuscript feel less mature than the science itself.

1. The translational bridge is too thin

We often see strong mechanistic work where the clinical implications are plausible but not yet structurally carried by the evidence.

2. The biomarker story is not actionable enough

Large-scale molecular characterization and biomarker studies are in scope, but editors still need a clear reason the work changes oncology thinking or decision-making.

3. The clinical claim outruns the dataset

Papers often lose force when the manuscript asks the reader to believe treatment, resistance, or patient-selection implications that the data only partially support.

Before submission, a translational oncology readiness check can tell you whether the problem is bridge strength, actionability, or journal level.

In our pre-submission review work with translational oncology, tumor immunology, molecular oncology, biomarker, resistance, personalized medicine, and large-scale tumor-characterization manuscripts targeting Journal of Experimental and Clinical Cancer Research, three patterns show up repeatedly before peer review begins. Official guidance explains JECCR's bench-to-bedside scope, data-availability expectations, declarations, and supporting-information package; the harder readiness question is whether the submission proves translational oncology rather than merely labeling itself that way.

This guide tells you what Journal of Experimental and Clinical Cancer Research editors look for before peer review; the review tells you whether YOUR paper passes the translational oncology, declaration, and reviewer-suggestion checks before upload. Paid Manusights reviews include a 60-day money-back guarantee; submitted manuscripts are not used for model training.

Translational oncology bridge left rhetorical

In our pre-submission review work with oncology manuscripts targeting Journal of Experimental and Clinical Cancer Research, the most common failure pattern is a real cancer-biology result whose translational bridge is still rhetorical. The abstract mentions therapy, diagnosis, resistance, patient selection, prognosis, or prevention, but the figures and methods still read mainly as cell biology, animal modeling, or molecular characterization. JECCR's official scope is clear that the journal wants significant advances in basic cancer research with a translational bridge from laboratory to clinic. That means the bridge must be carried by evidence, not only by discussion language.

The manuscript components that decide this are the title, abstract, first figure, methods, ethics statement, data-availability statement, and cover letter. A JECCR-ready abstract should say what oncology decision or clinical understanding changes if the result is correct. The first figure should connect the mechanism to tumor progression, metastasis, immune response, resistance, biomarker use, therapeutic targeting, or patient stratification. The methods should make model choice, cell-line breadth, human tissue use, clinical annotation, and statistics legible. If the better adjacent owner is Cancer Research, Molecular Cancer, Oncogene, Clinical Cancer Research, BMC Cancer, or a disease-specific oncology journal, the cover letter should make the JECCR choice explicit. This failure pattern is often solvable, but only if the manuscript turns translational language into a visible evidence chain.

Check whether your Journal of Experimental and Clinical Cancer Research manuscript passes the translational-bridge screen →

Biomarker or omics result without decision value

In our pre-submission review work with biomarker, multi-omics, tumor microenvironment, immunotherapy, targeted-therapy, and resistance manuscripts targeting Journal of Experimental and Clinical Cancer Research, the second recurring failure is a broad dataset without a clear oncology decision. A manuscript can include transcriptomics, proteomics, spatial profiling, methylation, metabolomics, single-cell analysis, or large public cohorts and still feel under-built if the result does not change diagnosis, prognosis, treatment selection, resistance interpretation, trial stratification, or mechanism-guided follow-up. JECCR lists biomarkers, response and resistance, personalized medicine, tumor immunotherapy, and large-scale molecular characterization in scope, but those areas still need an actionable translational endpoint.

The fix is to make the decision value visible across manuscript components. The abstract should state the cancer type, molecular feature, clinical or therapeutic question, validation layer, and likely use case. The figures should avoid presenting heat maps, signatures, or pathway enrichment as an endpoint by themselves. The methods should show cohort definition, validation logic, statistical controls, model calibration, and data-access details. The cover letter should say whether the manuscript should be read as biomarker discovery, response prediction, resistance mechanism, target validation, immunotherapy biology, or personalized medicine. Redirect targets such as Clinical Cancer Research, Cancer Research, Molecular Cancer, Nature Communications, or a disease-specific oncology journal may be stronger when the decision value is narrower or the clinical validation is not yet mature. JECCR becomes a stronger target when the paper's omics or biomarker component changes the reader's next oncology decision.

Check whether your Journal of Experimental and Clinical Cancer Research manuscript passes the biomarker-decision-value screen →

Declarations and reviewer identity package under-built

In our pre-submission review work with JECCR-targeted manuscripts, the third pattern is an operational package that makes the science look less mature than it is. Springer Nature and JECCR guidance put real weight on declarations, ethics approval, consent, data availability, competing interests, funding, author contributions, acknowledgements, reviewer suggestions, and supporting information. A manuscript can have a credible translational result and still create avoidable resistance if the ethics and disclosure package is incomplete, if data availability is vague, or if reviewer suggestions lack institutional email addresses, ORCID IDs, Scopus IDs, or other identity-verification signals.

For JECCR, this is not just administrative tidiness. Translational oncology manuscripts often involve human tissue, animal models, clinical annotations, regulated datasets, patient consent, imaging, omics repositories, or therapy-response claims. The methods, declarations, supplementary files, and cover letter should therefore work together. The package should state the ethics approval route, consent status, animal-use approvals where relevant, repository accessions, code or data restrictions, competing interests, funding, CRediT roles, and why suggested reviewers can fairly evaluate the work. If the paper depends on genomic data, proteomic data, clinical trial information, or patient-derived material, the supporting files should not make editors chase basic provenance. Nearby alternatives such as BMC Cancer, Oncogene, Cancer Letters, Clinical and Translational Medicine, or disease-specific oncology journals may be better if the translational bridge is narrow, but JECCR submissions need this operations layer to support the bench-to-bedside claim.

Check whether your Journal of Experimental and Clinical Cancer Research manuscript passes the Sullivan-pass substance screen →

JECCR requires these at first submission:

• main manuscript file in BMC Microsoft Word template format (or LaTeX equivalent)
• cover letter explaining why the manuscript should be published in JECCR, any issues relating to journal policies, declaration of any potential competing interests, confirmation that all authors have approved the submission, and confirmation that the content has not been published or submitted elsewhere
• author byline with full names, ORCID iDs (recommended for all co-authors), and CRediT contribution statement
• structured abstract per BMC format (Background / Methods / Results / Conclusions)
• ethics statements: IRB approval for human-subjects work and informed consent; IACUC approval for animal protocols; biosafety declarations for regulated organisms; clinical-trial registry references (ClinicalTrials.gov, ISRCTN, or equivalent) for trial reports
• patient consent for case-based content (mandatory)
• competing-interests declaration covering financial and non-financial interests, industry consulting, equity, and licensing
• data and code availability statements with deposit accessions (genomic data at GEO/SRA/EGA, proteomic data at PRIDE, etc.)
• suggested reviewers with institutional email addresses where possible (or ORCID/Scopus IDs to verify identity)
• declaration of generative AI use in the writing process
• APC funding declaration, institutional agreement information, funder grant, author-paid route, or waiver context where relevant
• for revised submissions, point-by-point reviewer response and marked-up manuscript

The supporting-information guidance asks authors who suggest reviewers to provide institutional email addresses where possible, or information such as ORCID or Scopus ID that helps the editor verify identity. For JECCR, this matters because reviewer-suggestion quality is part of the package's trust signal, not a throwaway portal field.

Run a JECCR pre-submission readiness check before clicking submit to verify the package meets JECCR's translational-oncology bar.

JECCR publishes rapid decision metrics, including a median first editorial decision signal on the journal home page and broader first-decision messaging on the about page. Treat those metrics as a reason to make the package legible before upload, not as a promise about any individual manuscript. The practical timeline below separates upload mechanics from the translational-oncology screen.

Day 0 to 2: Editorial Manager intake and BMC editorial-office technical check

The platform performs automated checks (template compliance, declarations, ethics references, ORCID linking). BMC editorial staff verify the cover letter, ethics statements, and reviewer-suggestion identity verification. Submissions with missing IRB/IACUC references or third-party submissions are returned at this stage. The 2-day median first-decision target is set here.

Day 2 to 14: Section Editor desk-screen

A Section Editor (matched to translational oncology, basic cancer biology with translational hook, tumor immunology, cancer pharmacology, or clinical oncology) reviews scope fit, translational rigor, and the bench-to-bedside bridge that distinguishes JECCR from Cancer Research or narrow-specialty oncology journals.

Week 2 to 8: External peer review

Manuscripts that pass desk-screen go to 2-3 reviewers under single-blind peer review. The BMC reviewer pool emphasizes both translational and clinical-oncology expertise.

Week 8 to 14: Decision and revision rounds

First decisions arrive at the BMC median window, typically as major or minor revision. Revision cycles add 4-8 weeks. Authors may file a formal appeal through BMC's standard appeal procedure.